The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16363 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Chung-Feng Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hepatobiliary, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis C, Diabetes Mellitus, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Science and Technology Council, Ministry of Health and Welfare, Taiwan, The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.
Abstract (Originalsprache)
Background and Aim The prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) and its interplay with hepatitis B virus (HBV) and hepatitis C virus (HCV) in terms of liver disease severity is elusive.
Methods
A mass surveillance program was conducted in a viral hepatitis endemic area. The objective was to identify MAFLD/non‐MAFLD subjects with advanced liver disease.
Results
Two thousand two hundred and forty‐two (41.7%) of the 5378 subjects were identified as having MAFLD, and 375 (7.0%) had advanced liver disease. The proportions of anti‐HCV and HBsAg seropositivity were 19.3% and 9.7%, respectively. The proportions of advanced fibrosis in subjects with non‐viral hepatitis (NBNC), HBV and HCV infection were 2.8%, 5.7% and 23.4%, respectively. Subjects with MAFLD had a significantly higher proportion of advanced fibrosis (8.7% vs 5.7%, P < 0.001). Factors associated with advanced fibrosis included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7–6.0, P < 0.001), male sex (OR/CI: 1.3/1.0–1.7, P = 0.019), anti‐HCV seropositivity (OR/CI: 5.9/4.6–7.5, P = 0.019), MAFLD‐lean metabolic dysregulation (MS) (OR/CI: 2.6/1.3–5.2, P = 0.005; compared with the non‐MAFLD group) and MAFLD‐diabetes (OR/CI: 1.5/1.1–2.1, P = 0.008; compared with the non‐MAFLD group). MAFLD did not aggravate liver disease severity in patients with viral hepatitis. However, among NBNC subjects, factors associated with advanced liver disease included MAFLD‐lean MS group (OR/CI: 9.1/2.4–34.6, P = 0.001; compared with non‐MAFLD group) and MAFLD‐DM group (OR/CI: 2.0/1.2–3.2, P = 0.004; compared with non‐MAFLD group).
Conclusions
MAFLD patients with diabetes and metabolic dysregulation had a higher risk of advanced liver disease. The effect was more significant in non‐viral hepatitis subjects in a community level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Hepatobiliary, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Program in Translational Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Faculty of Internal Medicine and Hepatitis Research Center, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwa…
ORCID-Profile: Chung-Feng Huang, Chih-Wen Wang, Tyng-Yuan Jang, Ming-Lun Yeh, Po-Yao Hsu, Jee-Fu Huang, Ming-Lung Yu
Förderung
- National Science and Technology Council
- Ministry of Health and Welfare, Taiwan
- The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan
- Ministry of Health and Welfare
Zitieren
APA
Huang, C. F., Liang, P. C., Tsai, P. C., Wei, Y. J., Huang, C. I., Wang, C. W., Jang, T. Y., Yeh, M. L., Hsu, P. Y., Hsieh, M. Y., Lin, Y. H., Dai, C. Y., Chuang, W. L., Huang, J. F., & Yu, M. L. (2024). The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16363
Vancouver
Huang CF, Liang PC, Tsai PC, Wei YJ, Huang CI, Wang CW, et al. The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16363
BibTeX
@article{Huang2024,
author = {Huang, Chung-Feng and Liang, Po-Cheng and Tsai, Pei-Chien and Wei, Yu-Ju and Huang, Ching-I and Wang, Chih-Wen and Jang, Tyng-Yuan and Yeh, Ming-Lun and Hsu, Po-Yao and Hsieh, Ming-Yen and Lin, Yi-Hung and Dai, Chia-Yen and Chuang, Wan-Long and Huang, Jee-Fu and Yu, Ming-Lung},
title = {The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16363}
}
EUVIMED